Abstract
Background Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting postmarketing adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During the coronavirus diseases 2019 (COVID-19) pandemic, VAERS got more attention as its important role in monitoring the safety of the vaccines. Thus, the aim of this study was to investigate VAERS patterns, reported AEFIs, adverse events of special interest (AESIs), impact of different pandemics since its inception, and surveillance rate of serious vs nonserious AEFIs.
Methods This was an observational study using VARES data from 2/7/1990 to 12/11/2021. Patterns of reports over years were first described, followed by a comparison of reports statistics per year. Furthermore, a comparison of incidents (death, ER visits, etc.) statistics over years, in addition to statistics of each vaccine were calculated. Moreover, each incident’s statistics for each vaccine were calculated and top vaccines were reported. Finally, survival analysis utilizing cox regression was done, in addition to AESIs distribution stratified by age groups and gender. All analyses were conducted using R (Version 1.4.1717) and Excel for Microsoft 365.
Results There were 1,396,280 domestic and 346,210 non-domestic reports during 1990-2021, including 228 vaccines. For both domestic and non-domestic reports, year of 2021 had the highest reporting rate (48.52% and 70.33%), in addition a notable changes in AEFIs patterns were recorded during 1991, 1998, 2000, 2006, 2009, 2011, and 2017. AEFIs were as follow: deaths (1.00% and 4.08%), ER or doctor visits (13.37% and 2.27%), hospitalizations (5.84% and 27.78%), lethal threat (1.42% and 4.38%), and disabilities (1.4% and 7.96%). Pyrexia was the top reported symptom during the past 31 years, except for 2021 where headache was the top one. COVID-19 vaccines namely Moderna, Pfizer-Biontech, and Janssen were the top 3 reported vaccines with headache, pyrexia, and fatigue as the top associated AEFIs. Followed by Zoster, Seasonal Influenza, Pneumococcal, and Human papillomavirus vaccines. Myocarditis or Pericarditis were the top reported AESIs (26.95% and 25.84%). Male (HR:1.15, 1.14 - 1.16) for domestic (HR:1.23, 1.22 -1.25) for nondomestic have a higher probability of having serious AEFIs. In addition, age group ≤ 5 years old in domestic and >84 years old in nondomestic have a higher probability of having AEFIs compared to other age groups.
Conclusions The large data available in VARES make it a useful tool for detecting and monitoring vaccine AEFIs. However, its usability relies on understating the limitations of this surveillance system, the impact of governmental regulations, availability of vaccines, and public health recommendations on the reporting rate.
I. Introduction
The Council for International Organizations of Medical Sciences (CIOMS) defined an adverse event following immunization (AEFI) as “any untoward medical occurrence which follows immunization, and which does not necessarily have a causal relationship with the usage of the vaccine. AEFI may be any unfavorable or unintended sign, abnormal laboratory finding, symptom or disease” 1–3.
To identify AEFIs, vaccine testing for safety is conducted in laboratories on animals and humans in clinical trials, similar to medications’ approval process 2,4–8. Three phases of clinical trials are required to determine the tested vaccine’s effectiveness (immunogenicity) and safety (including adverse events) 2,4–7,9.
The United States Food and Drug Administration (USFDA) requires this premarketing evaluation process before granting any vaccine licensure 2,8,9. Such evaluations effectively detect the most common AEFIs of tested vaccines 2,10. However, some AEFIs cannot be detected easily, especially rare ones, either due to the sample size or duration of premarketing trials 8,10,11.
The Vaccine Adverse Event Reporting System (VAERS) is an early warning system that the USFDA and Centers for Disease Control and Prevention (CDC) jointly established in 1990. The main purpose of this system is to collect postmarketing AEFIs reports 12.
The VAERS received more attention following the coronavirus disease 2019 (COVID-19). Majority of these vaccines were approved under emergency use authorization (EUA), which require health care providers to record certain AEFIs in the VAERS, including death 13–15.
Since the establishment of the VAERS, no study has been conducted to evaluate it comprehensively. Therefore, we aimed to provide a descriptive analysis of VAERS data from its inception to 2021, focusing on pattern analysis of reported vaccines, reported AEFIs, reported admissions, and other related variables. We also aimed to describe the most frequently reported symptoms and vaccines that have been associated with each of them, and adverse events of special interest (AESIs) associated with COVID-19. Last, we aimed to calculate serious AEFIs survival probability.
II. Materials and Methods
A. Study Design
This was a retrospective observational study using the VAERS from the first available report in the data (July 2, 1990) to the last available report (November 12, 2021).
B. Data Sources
This study includes data from VAERS, which is a passive AEFI reporting system that the USFDA and CDC established in 1990. These multidimensional data are reported by individual health care providers or the public when someone experiences an AEFI, without a confirmation of the AEFI’s real cause. Data available on the website is formatted as ready-to-download comma-separated value (CSV) files, which can be imported to the CDC WONDER online search tool. VAERS data are available as domestic and nondomestic data. More than 99% of nondomestic data is reported by vaccine manufacturers. Furthermore, these data are divided for each year into three files: data, symptoms, and vaccine information. Table 1 presents variables available in VAERS data that we have used in this paper. The code of federal regulations (CFR) defines a lethal threat as any adverse event or condition that puts the patient or subject in immediate danger of death. In addition, it defines disability as a long-term or considerable inability or disturbance of the subject’s ability to carry out normal life functions 7. Moreover, an AESI is a condition or event that occurs in certain people after vaccination and has the potential to be causally linked to a vaccine 16–18. AESIs we included in this study are anaphylaxis, appendicitis, bell’s palsy, deep vein thrombosis (DVT), disseminated intravascular coagulation, encephalomyelitis, Guillain-Barré syndrome, immune thrombocytopenia, myocardial infarction, myocarditis or pericarditis, narcolepsy, pulmonary embolism, non-hemorrhagic or hemorrhagic stroke, and transverse myelitis 16–18.
VAERS data variables names and descriptions
C. Data reprocesses
VAERS data is multidimensional data, meaning one report may contain several symptoms or vaccines. First, for domestic data, we merged symptoms and vaccine files based on VAERS_ID. Then we separated reports containing multiple vaccines—because no clear information is available about which vaccine triggered those events—in a way that each vaccine reported in them presents the same event information. We followed the same steps with nondomestic files. Reprocessing completed using R studio (version 1.4.1717).
D. Data analysis
We first described patterns of reports over the years by calculating the number of reports per year and then placing that number on a line chart. We then calculated a comparison of reports statistics per year as follows:
Furthermore, we compared incident (death, ER visits, etc.) rates in a year as follows:
In addition, we calculated yearly statistics for each vaccine, and we then described the most common vaccine patterns using line charts.
Moreover, we calculated the incident statistics (death, ER visits, etc.) for each vaccine, and we reported the most common vaccines.
We made these calculations and created these charts using Excel for Microsoft 365. We excluded 2019 coronavirus disease (COVID-19) vaccines from the charts of the most common vaccine patterns due to their recent development.
Moreover, we performed a survival (time to event) analysis, were individuals followed up from the vaccination date up to the event date (onset of AEFIs), using survival package in R studio19. Based on FDA protocol recommendation, we restrict follow up to 365 days 16,20. All data in VAERS are for confirmed events, because of that we used non serious AEFIs – instead of no event - as a comparator to serious AEFIs to calculate the probability of survival 19.
Last, we calculated distribution of AESIs among all vaccines, and their distribution to COVID vaccines.
III. Results
A. Domestic data
There were 1 396 280 reports from 1990 through 2021. Reports included 228 vaccines. The
most reports were recorded in 2021 (n = 677 514, 48.52%), followed by 2020 (n = 50 205, 3.60%), 2018 (n = 49 137, 3.52%), 2019 (n = 48 443, 3.47%), and 2016 (n = 45 706, 3.27%).
Most of the samples were from female subjects (60.90%), and the subjects’ average age was 27.8 years (max = 119, min = <1 month). Supplementary figure 1 shows the number of domestic reports per year.
COVID-19 vaccines were the top 3 reported vaccines—Moderna (19.81%), Pfizer-Biontech (19.45%), and Janssen (4.46 %)—followed by Zoster (Shingrix; 4.10%), seasonal influenza (Fluzone; 2.88%), Pneumo (Pneumovax; 2.87%), Zoster live (Zostavax; 2.41%), HPV (Gardasil; 2.38%), Varicella (Varivax; 2.08%), and measles-mumps-rubella (MMR II; 1.96%). Supplementary table 2 presents the number of domestic and nondomestic reports per vaccine.
Reported deaths
The total number of reported deaths is 13 926 (1.00%), with the most deaths reported in 1990 (3.62%), followed by 1991 (2.62%), 1994 (2.19%), 1993 (2.16%), and 1992 (2.04%). Reported deaths continuously decreased over the past 30 years except for 2021, when the percentage of reported deaths increased. Supplementary figure 2 shows pattern of reported death over the past 31 years.
The top vaccines in terms of reported deaths are Pfizer-Biontech (27.98%), Moderna (24.01%), Janssen (7.16%), seasonal influenza, no brand (3.24%), and Fluzone (2.91%). Supplementary figure 3 presents the top vaccines in terms of reported deaths, excluding COVID vaccines due to their recent addition. Supplementary table 3 presents the number of reported deaths per vaccine per year.
Reported ER or doctor office visits
The total number of reported ER visits is 186 645 (13.37%), with the most ER visits occurring in 2007 (47.31%). Supplementary figure 4 shows the percentage of ER visits per year.
Fluzone (7.22%) is the top vaccine in terms of reported ER visits, followed by Gardasil (6.00%), Pneumovax (4.98%), Varivax (4.05%), and MMRII (4.03%). Supplementary figure 5 presents the top five vaccines in terms of reported ER visits. In addition, supplementary table 4 presents the number of domestic reported ER or doctor visits per vaccine per year.
Reported hospitalizations
The number of reported hospitalizations is 81 538 (5.84%), with a continuous decrease in the hospitalization rates and the largest hospitalization rate occurring in 1990 (12.13%). Supplementary figure 6 shows pattern of domestic reported hospitalization over years.
The highest number of average hospitalization days (mean = 12.7 days) occurred in 2021, compared to an average of hospitalization days of 6.3 over the past 30 years. COVID vaccines are the top vaccines in terms of hospitalization—Pfizer-Biontech (28.09%), Moderna (20.34%), and Janssen (6.62%)—followed by seasonal influenza, no brand (2.31%), Fluzone (2.28%), and Gardasil (2.07%). Supplementary table 5 presents the number of reported hospitalizations per year with the average number of hospitalization days. In addition, supplementary figure 7 presents the top vaccines in terms of reported hospitalization.
Reported lethal threats
The number of reported lethal threats is 19 872 (1.42%), with the most lethal threats occurring in 1999 (2.56%), followed by 2.03% in 1995 and 2.00% in 1994. Supplementary figure 8 presents the pattern of reported lethal threats over years.
COVID vaccines are the top vaccines in terms of lethal threats—Pfizer-Biontech (22.35%), Moderna (18.23%), and Janssen (6.04%)—followed by Fluzone (4.13%), Gardasil (3.76%), and seasonal influenza, no brand (2.21%). Supplementary figure 9 presents the top five vaccines in terms of reported lethal threats per years. In addition, supplementary table 6 presents the number of domestic reported lethal threats per vaccine per year.
Reported disabilities
The total number of reported disabilities is 22 639 (1.4%), with the most frequently reported disabilities occurring in 1990 (3.95%), followed by 2002 (2.87%) and 2001 (2.81%). Supplementary figure 10 presents the pattern of reported disabilities over years.
Pfizer-Biontech is the top vaccine in terms of reported disabilities (20.04%), followed by Moderna (15.55%), Gardasil (5.35%), Janssen (4.58%), and Zostavax (4.29%). Supplementary figure 11 shows the top five vaccines in terms of reported disabilities. In addition, supplementary table 7 presents the number of domestic reported disabilities per vaccine per year.
Most frequently reported symptoms over the years
The total number of reported symptoms is 3 449 887. Table 8 lists the top vaccines in terms of reported symptoms. From 1990 through 2000, pyrexia was the most frequently reported AEFI (8.41%), followed by injection site hypersensitivity (4.29%), rash (3.36%), injection site edema (3.14%), and vasodilatation (2.88%). However, from 2001 through 2010, erythema was the most frequently reported AEFI (7.16%), followed by pyrexia (4.59%), injection site pain (4.57%), injection site swelling (2.55%), and rash (2.16%). Finally, from 2011 through 2020, pyrexia was the most frequently reported AEFI (3.33%), followed by injection site pain (2.85%), injection site erythema (2.73%), incorrect product storage (2.15%), and injection site swelling (2.04%). Table 9 presents the most frequently reported AEFIs and the associated vaccines.
Top vaccines in reported symptoms
Top reported AEFI with top related vaccines
B. Nondomestic data
There were 346 210 nondomestic reports from 1990 through 2021. Reports included 214 vaccines. 2021 had the most reports (n = 243 500, 70.33%), followed by 2019 (n = 9,569, 2.76%), 2018 (n = 8,673, 2.512%), 2020 (n = 8,111, 2.34%), and 2016 (n = 7,991, 2.31%). Most of the sample (61.15%) came from female subjects, and the average age was 20.94 years. Supplementary figure 12 presents the number of reports per year. In addition, table 2 presents number of domestic and nondomestic reports per vaccine.
The top vaccine in terms of nondomestic reports is Pfizer-Biontech (57.64%), followed by Moderna (9.04%), Gardasil (2.57%), Janssen (2.48%), and seasonal influenza, no brand name (1.76%).
Reported deaths
The total number of reported deaths is 14 125 (4.08%). The most deaths occurred in 1991 (10.17%), followed by 1993 (9.32%), 1994 (8.70%), 1990 (8.16%), and 1992 (8.00%). Supplementary figure 13 presents pattern of nondomestic reported death over years. The top vaccine in terms of reported deaths is Pfizer-Biontech (61.27%), followed by Moderna (6.77%), Janssen (3.88%), seasonal influenza, no brand name (2.43%), and Pneumovax (1.67%). Supplementary figure 14 shows the top vaccines in terms of reported deaths per year. In addition, supplementary table 10 presents the number of nondomestic reported deaths per vaccine per year.
Reported ER or doctor office visits
The total number of reported ER or doctor office visits is 7,868 (2.27%), with the most ER or doctor visits occurring in 2015 (24.50%), followed by 2014 (19.83%), 2013 (18.07%), 2016 (17.72%), and 2000 (11.42%). Supplementary figure 15 shows pattern of nondomestic reported ER or doctor visits over years.
The top vaccine in terms of reported ER or doctor visits is Gardasil (21.59%), followed by Pneumovax (9.13%), Infanrix Hexa (5.31%), seasonal influenza, no brand name (4.49%), and Rotateq (4.31%). Supplementary figure 16 presents the pattern of top vaccines in reported ER or doctor visits over the years. In addition, supplementary table 11 presents the number of nondomestic reported ER or doctor visits per vaccine per year.
Reported hospitalization
The total number of reported hospitalizations is 96 166 (27.78%) with hospitalization occurring most frequently in 1994 (76.40%), followed by 1993 (72.67%), 1997 (68.44%), 1995 (66.54%), and 1996 (65.07%). Supplementary figure 17 shows pattern of nondomestic reported hospitalization over the years.
The average number of hospitalization days in nondomestic reports was 6.10, with the longest average hospital stay occurring in 1992 (mean = 19.67).
Pfizer-Biontech is the top vaccine in terms of reported hospitalizations (45.80%), followed by Moderna (8.12%), Gardasil (3.36%), Pneumovax (2.46%), and Infanrix Hexa (2.32%). Supplementary figure 18 presents patterns of the top vaccines in terms of nondomestic reported hospitalization. In addition, supplementary table 12 presents the number of nondomestic reported hospitalizations per vaccine per year.
Reported lethal threats
The number of reported lethal threats is 15 151 (4.38%), with the most lethal threats occurring in 1992 (17.60%), followed by 1991 (10.17%), 1994 (9.94%), 1995 (6.99%), and 2000 (6.85%). Supplementary figure 19 presents the pattern of nondomestic reported lethal threat over the years.
COVID-19 vaccines were the top vaccines in terms of reported lethal threats—Pfizer-Biontech (60.89%), Moderna (9.16%), and Janssen (2.83%)—followed by Infanrix Hexa (1.89%) and seasonal influenza, no brand name (1.80%). Supplementary figure 20 presents the top vaccines in terms of nondomestic lethal threats. In addition, supplementary table 13 presents the number of nondomestic reported lethal threats per vaccine per year.
Reported disabilities
The total number of reported disabilities is 27 545 (7.96%), with reported disabilities occurring most frequently in 1990 (22.45%), followed by 2001 (18.21%), 2002 (16.71%), 1999 (15.76%), and 2003 (14.59%). Supplementary figure 21 presents pattern of nondomestic reported disabilities over the years.
Pfizer-Biontech is the top vaccine in terms of nondomestic reported disabilities (59.52%), followed by Moderna (10.36%), Gardasil (4.76%), Engerix-B (3.42%), and Janssen (2.70%). Figure 22 presents the top vaccines in terms of nondomestic reported disabilities over the years. In addition, supplementary table 14 presents the number of nondomestic reported hospitalizations per vaccine per year.
Most frequently reported nondomestic reported symptoms over the years
The total number of nondomestic reported symptoms is 2 159 135. Table 15 presents the top vaccines in terms of reported symptoms. From 1990 through 2000, pyrexia was the most frequently reported AEFI (5.27%), followed by infection (2.44%), abnormal laboratory test (2.4%), convulsion (1.88%), and vomiting (1.49%). Pyrexia was also the most frequently reported AEFI (4.28%) from 2001 through 2010, followed by vomiting (1.51%), increased body temperature (1.47%), crying (1.41%), and pallor (1.37%). From 2011 through 2021, pyrexia was again the most frequently reported AEFI (3.8%), followed by vomiting (1.40%), headache (1.18%), crying (1.16%), and diarrhea (0.96%). Finally, in 2021, the most frequently reported AEFI was SARS-CoV-2 test (4.59%), followed by headache (3.18%), fatigue (2.57%), pyrexia (2.55%), and nausea (1.82%). Table 16 presents the most frequently reported AEFIs with the most frequently associated vaccines.
Top vaccines in non-domestic reported symptoms
Top non-domestic reported AEFI with top related vaccines
C. Survival Analysis Results
Domestic reports with complete vaccination and onset data are 1 121 698, while for nondomestic data they are 262 723. Probability of having non serious AEFIs has its highest value at the vaccination’s day, with 93% probability of having non serious AEFIs in domestic data, and 85.91% in nondomestic data. It continuously decreased after that to its minimal 10.40% and 6.08% at the end of the following up window, for domestic and nondomestic data, respectively. However, for serious AEFIs they have a proportional relation to time, where they have their lowest values in the vaccination’s day, ranging from 0.09% to 5.18% for domestic data and ranging from 0.39% to 8.00% for nondomestic data. For domestic data ER or Doctor visit was the highest serious AEFIs by 33.84%, and for nondomestic data hospitalization was the highest by 54.10% at the end of the follow up window. Table 17 contains survival analysis of both domestic and nondomestic data. In addition, supplementary table 18 contains cox regression results of both domestic and nondomestic data. Both in domestic and nondomestic data, males have more probability to have AEFIs than females (HR: 1.15, 1.14 - 1.16) in domestic, and (HR: 1.23, 1.22 -1.25) in nondomestic. While for age group, in domestic data age group ≤ 5 years have a higher probability of having AEFIs compared to other groups. However, in nondomestic data age group > 84 years have a higher probability of having AEFIs compared to other groups (HR:2. 15, 2.07 - 2.23).
Survival analysis of domestic and nondomestic data
D. Adverse event of special interest (AESIs)
Out of 3 449 887 domestic reported symptoms 17 611 (0.51%) were AESIs, 9 665 (54.88%) were associated with COVID-19 vaccines. Table 19 shows distribution of domestic AESIs associated with COVID-19 stratified by gender and age. While for nondomestic reported symptoms out of 2 159 135 there were 35 810 (1.66%) AESIs, 31 511 (87.99%) were associated with COVID-19 vaccines. Table 20 shows distribution of nondomestic AESIs associated with COVID-19 stratified by gender and age.
Survival analysis of domestic and nondomestic data
Survival analysis of domestic and nondomestic data
Discussion
Vaccination saves 2.5 million children from death each year, according to WHO estimates 21–24. Moreover, it is the most effective technique for preventing infectious diseases and reducing their associated mortality and morbidity rate 21,23,24. However, threatening factors associated with vaccinations, such as AEFIs, could have a negative impact on vaccination rates 21,23. Here, we describe VAERS data and evaluate their usability. We also examine COVID19’s impact on the reporting patterns.
The VAERS provides a wealth of information for analyzing AEFIs and their patterns over time 10,12,25. Such a surveillance system with a large data set can be utilized for event detection and generation to investigate and evaluate vaccine safety, ultimately helping develop regulatory laws and actions to minimize the risks associated with these vaccines 10,25–27. Descriptive and pattern analysis of raw VAERS data combined with data visualization showed several intriguing patterns over the previous 31 years. This study’s outcomes provide some insights into and can guide further research on certain vaccines and AEFIs.
The COVID-19 vaccine was released under the EUA, which requires the reporting of any AEFI occurrence 13,15. The VAERS data shows a huge increase in reporting in 2021, accounting for 48.52% of domestic and 70.33% of nondomestic reports over the past 31 years. Furthermore, COVID-19 vaccines were the most frequently reported vaccines, accounting for 43.72% of domestic and 69.16% of nondomestic total reported vaccines.
A major component of the VAERS design is the identification of serious AEFIs, such as death, hospitalization, lethal threat, and permanent disability 28. The reporting rate of domestic deaths steadily decreased for 30 years until 2021, where it started rising. However, underreporting clearly occurred, with reported deaths representing only 1% of the data. We suspect underreporting in the nondomestic data as well, with reported deaths representing only 4.08% of the data. A continuous decrease in reported death occurred in the nondomestic data until 2000. The fact that the pneumococcal conjugate vaccine was released in 2000 may explain this increase in reported deaths, which also occurred in 2021, when the COVID-19 vaccine was released 13,14,29–31. The number of Pnumovax-associated deaths increased in 2000, confirming our suggestion 29–31. Another pattern worth noting is that reported domestic deaths associated with influenza vaccines increased in 2011. We found a similar increase in 2019. Influenza H1N1 was a pandemic disease that struck between 2009 and 2010; as a result, the CDC updated its 2010-2011 vaccination recommendations 32–34. The CDC recommended administering influenza vaccines to all persons 6 months or older 35,36. In 2019, the US health strategy to manage the COVID-19 pandemic included the influenza vaccination to minimize influenza-related respiratory diseases and optimize health care services for COVID-19 patients 37. Furthermore, nondomestic reported deaths show an interesting pattern associated with DTP, whose occurrence sudden increased in 2018, possibly due to an increase in pertussis cases in 2018 and 2019, as the CDC reported more than 15 600 cases per year 38,39.
Domestic ER or doctor office visit reports show an upward trend from 1990 to 2007, then show a downward pattern until they flatten. However, for nondomestic ER or doctor office visits, the pattern fluctuated steadily until 2011, when it began to rise, reaching its peak in 2015. Among the vaccines most frequently associated with nondomestic reported ER or doctor visits, the HPV vaccine showed a similar pattern. In addition, a similar increase in domestic reported ER or doctor visits was associated with HPV from 2006 to 2008, with a steady decline following. The USFDA first approved the HPV vaccine in 2006, which may explain the increase in domestic ER or doctor visits 40. In 2011, the Advisory Committee on Immunization Practices (ACIP) updated the recommendations for HPV vaccination to include boys, which could have led to an increase in vaccinations and associated ER visits 41–44.
Over the last 31 years, domestic and nondomestic hospitalization reports have steadily declined. However, supporting our previous interpretations, domestic data on the HPV vaccine showed an increased rate of hospitalization from 2006 to 2015 41–44. Furthermore, the influenza vaccine was associated with a similar increase in 2011, followed by a steady decline. In addition, the USFDA approved a new Zoster (Shingrix) vaccine in 2017, which could explain the increase in hospitalizations rate associated with the Zoster in the same year 45. However, we found no clear cause for the sudden increase in 2015.
Reports of domestic lethal threats increased in 1998. A similar trend occurred with the hepatitis B vaccine. This increase may have occurred due to the ACIP’s recommendation in 1998 to expand the children vaccination program to include the hepatitis B vaccine 46. However, we found a similar increase in reports of nondomestic lethal threats in 1991, when the ACIP first recommended hepatitis B vaccines for all infants 47.
Domestic disabilities showed a similar trend as lethal threats associated with hepatitis B vaccines in 1991 and 1998 46–48. We found another interesting increase in 1999 and a similar pattern associated with the Lyme vaccine, which the FDA approved in 1998 but its manufacturer has since withdrawn 49,50. We also found a similar pattern of Zoster-associated disabilities and lethal threat pattern from 2006 to 201545. In 2005, we found an increase in the administration of the anthrax vaccine, which could have occurred due to the EUA’s extension of the anthrax-adsorbed vaccine, which the USFDA announced that year 51. Moreover, nondomestic reported disabilities show a similar pattern associated with the Zoster vaccine 45. We found another interesting pattern described by an increase in nondomestic disabilities in 1998, which was associated with a similar pattern in hepatitis B and MMR II vaccines. Wakefield study results may affect the reporting pattern of MMR. The outcome of this study, which was published in 1998, showed that a behavioral and development disorder in children resulted from MMR 52,53.
In the domestic and nondomestic data, pyrexia was the most frequently reported AEFI over the past 30 years. Pyrexia is defined as an elevation of body temperature that exceeds the normal range due to the presence of a foreign substance in the body 54. This AEFI is expected as a part of the activated immune response 3,54–56. However, in 2021, headache was the most frequently reported AEFI and was mainly associated with COVID-19 vaccines 3,55–58. In the domestic data, injection site AEFIs were the most common 3,55. Furthermore, the nondomestic data shows a variety of symptoms, with vomiting being the commonly reported AEFI over the past 30 years 3,55,56. CDC estimated 0.48 cases of myocarditis per 100,000 after COVID-19 vaccination, and in this study results of AESIs analysis show that most most reported adverse event associated with COVID-19 was myocarditis or pericarditis which support these results59,60.
Results of our study show that most of AEFIs are nonserious and more than 80% of them appear within first few days following vaccination, which is consistent with results found in other articles 61–63. In addition, male and age group ≤ 5 years were more prone to serious AEFIs in consistent with findings from prior research 63,64. These findings could strengthen the argument for VARES’s efficient use.
Generally, stimulated reporting is noticeable in this study’s outcomes 25,26. Yearly patterns were mostly affected by the USFDA’s approval of vaccines such as the Lyme and HPV vaccines, CDC recommendations, such as administration of the H1N1 and DTP vaccines, and ACIP recommendations, such as administration of the HPV and HEB B vaccines. In addition, pandemic diseases, such as COVID-19 and H1N1, have a major impact on vaccination pattern 29–51,57. Finally, public research outcomes, such as in the case of the MMR vaccine, have a noticeable impact on vaccination rate 52,53.
Given that this is a passive reporting system, and that each report may contain information about several vaccines, we cannot confirm a causal relationship between a vaccine and its associated AEFIs 12,25,26. Incomplete reports and underreporting are a noticeable issue in these data sets, which can be seen clearly with serious AEFIs. In addition, most of the nondomestic data are reported by manufacturers to fulfill legal requirements, which could lead to misleading selective reporting and thereby impact nondomestic data more than domestic data 25. Although the VAERS uses MedDRA medical terminology, spelling mistakes and duplication (e.g., pyrexia and elevated body temperature) could have a negative impact on the data 12.
In conclusion, the VAERS is considered an important and useful tool in vaccine safety surveillance. However, the usability of VAERS data depends on users understating this surveillance system’s limitations and knowing how to interpret its results. Governmental regulations, availability of vaccines, and public health recommendations have the largest impact on reporting rates, which could be used to improve VAERS data.
Data Availability
All data produced are available online at https://vaers.hhs.gov/data.html
References
